Ad is loading...
JANX
Price
$48.76
Change
-$2.34 (-4.58%)
Updated
Nov 15 closing price
110 days until earnings call
SKYE
Price
$4.95
Change
-$0.56 (-10.16%)
Updated
Nov 15 closing price
Ad is loading...

JANX vs SKYE

Header iconJANX vs SKYE Comparison
Open Charts JANX vs SKYEBanner chart's image
Janux Therapeutics
Price$48.76
Change-$2.34 (-4.58%)
Volume$699.11K
CapitalizationN/A
Skye Bioscience
Price$4.95
Change-$0.56 (-10.16%)
Volume$419.77K
CapitalizationN/A
JANX vs SKYE Comparison Chart
Loading...
JANX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
JANX vs. SKYE commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JANX is a Sell and SKYE is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (JANX: $48.76 vs. SKYE: $4.95)
Brand notoriety: JANX and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JANX: 105% vs. SKYE: 109%
Market capitalization -- JANX: $2.56B vs. SKYE: $150.17M
JANX [@Biotechnology] is valued at $2.56B. SKYE’s [@Biotechnology] market capitalization is $150.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JANX’s FA Score shows that 0 FA rating(s) are green whileSKYE’s FA Score has 0 green FA rating(s).

  • JANX’s FA Score: 0 green, 5 red.
  • SKYE’s FA Score: 0 green, 5 red.
According to our system of comparison, SKYE is a better buy in the long-term than JANX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JANX’s TA Score shows that 4 TA indicator(s) are bullish while SKYE’s TA Score has 5 bullish TA indicator(s).

  • JANX’s TA Score: 4 bullish, 5 bearish.
  • SKYE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SKYE is a better buy in the short-term than JANX.

Price Growth

JANX (@Biotechnology) experienced а -9.57% price change this week, while SKYE (@Biotechnology) price change was -13.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

JANX is expected to report earnings on Mar 07, 2025.

SKYE is expected to report earnings on Nov 29, 2023.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JANX($2.56B) has a higher market cap than SKYE($150M). JANX YTD gains are higher at: 354.427 vs. SKYE (81.985). SKYE has higher annual earnings (EBITDA): -40.58M vs. JANX (-63.86M). JANX has more cash in the bank: 646M vs. SKYE (74.1M). SKYE has less debt than JANX: SKYE (5.07M) vs JANX (23.8M). JANX has higher revenues than SKYE: JANX (15.1M) vs SKYE (0).
JANXSKYEJANX / SKYE
Capitalization2.56B150M1,706%
EBITDA-63.86M-40.58M157%
Gain YTD354.42781.985432%
P/E RatioN/A9.34-
Revenue15.1M0-
Total Cash646M74.1M872%
Total Debt23.8M5.07M470%
FUNDAMENTALS RATINGS
SKYE: Fundamental Ratings
SKYE
OUTLOOK RATING
1..100
85
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
73
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
JANXSKYE
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 14 days ago
87%
Bullish Trend 10 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
JANX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRUZX16.890.23
+1.38%
PGIM Jennison Utility Z
ITEIX11.13N/A
N/A
VY® T. Rowe Price Equity Income I
HOVLX56.28-0.38
-0.67%
Homestead Value
FDGRX42.25-1.07
-2.47%
Fidelity Growth Company Fund
BIPSX38.06-3.30
-7.98%
ProFunds Biotechnology UltraSector Svc

JANX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with VKTX. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
-4.58%
VKTX - JANX
63%
Loosely correlated
-7.45%
DNLI - JANX
55%
Loosely correlated
-11.95%
LGND - JANX
45%
Loosely correlated
-3.24%
BEAM - JANX
44%
Loosely correlated
-8.59%
CDXS - JANX
41%
Loosely correlated
+3.74%
More

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with JANX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then JANX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
-10.16%
JANX - SKYE
34%
Loosely correlated
-4.58%
VKTX - SKYE
34%
Loosely correlated
-7.45%
AGTX - SKYE
23%
Poorly correlated
N/A
TARS - SKYE
22%
Poorly correlated
-3.90%
KALV - SKYE
22%
Poorly correlated
-3.16%
More